Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-930098

ABSTRACT

Objective:To explore the effect of Rehmanniae Radix combined with Scrophulariae Radix on renal microinflammation in diabetic nephropathy (DN) rats. Methods:50 Sprague Dawley (SD) rats were adaptively fed for 1 week, and then 10 rats were randomly selected as the blank control group, and the rest were treated with STZ intraperitoneal injection combined with high-fat diet to induce DN model. After 4 weeks, the successful modeled rats were randomly divided into model group, Rehmannia glutinosa Scrophularia group (5.25 g/kg) and metformin group (200 mg/kg), with 10 rats in each group. After 8 weeks of administration, fasting blood glucose was measured by blood glucose meter; microalbuminuria was measured by benzalkonium chloride turbidimetry; serum cystatin, TNF-α, IL-6 and hs-CRP levels were measured by ELISA kit; renal pathological changes were detected by HE staining, Masson staining and PAS staining; the expression of MCP-1, NF-κB (total) and p-NF-κB protein in renal tissue was detected by Western blot.Results:Compared with the model group, the body weight of rats in DHXS group was significantly decreased ( P<0.05). The content of fasting blood glucose[(18.06 ± 5.69) mmol/L vs. (29.42 ± 0.63)mmol/L], 24-hour urine protein [(11.02 ± 1.77)mg/d vs. (31.61 ± 0.65)mg/d], serum cystatin [(208.16 ± 12.07)ng/ml vs. (278.05 ± 19.33)ng/ml], TNF-α [(9.13 ± 1.46)pg/ml vs. (73.16 ± 8.30)pg/ml], IL-6[(4.27 ± 1.07)pg/ml], hs-CRP[(219.36 ± 22.02)ng/ml vs. (266.97 ± 15.80)ng/ml] in DHXS group were significantly decreased ( P<0.05), and the expression level of p-NF-κB (0.49 ± 0.07 vs. 0.84 ± 0.12) and MCP-1 (0.44 ± 0.02 vs. 0.64 ± 0.11) in renal tissue of rats in DHXS group were significantly reduced ( P<0.05). Conclusion:Rehmanniae Radix combined with Scrophulariae Radix can protect kidney by inhibiting the over activation of NF-κB, and reducing the expression of MCP-1 related protein to reduce renal micro inflammation.

2.
Aging (Albany NY) ; 12(24): 25730-25743, 2020 11 25.
Article in English | MEDLINE | ID: mdl-33234722

ABSTRACT

Cardamonin, a natural chalcone, is reported to induce apoptosis and inhibit cancer cell growth. However, the mechanisms underlying the therapeutic effects of cardamonin remain to be established. Here, we have focused on cardamonin-induced apoptosis in ovarian cancer cells, both in vitro and in vivo. The effects of cardamonin on cell cycle patterns and apoptotic responses of cells were assessed in this study. Western blot was employed to determine the effects of cardamonin on expression of cell cycle- and apoptosis-related proteins. Our results indicate that cardamonin suppresses cancer cell growth by inducing G2/M phase arrest and apoptosis through targeted inhibition of NF-κB and mTOR pathways. The collective findings provide novel insights into the pathways responsible for the anticancer effects of cardamonin and support its potential utility as a clinical therapeutic agent for ovarian cancer.


Subject(s)
Apoptosis/drug effects , Carcinoma, Ovarian Epithelial/metabolism , Chalcones/pharmacology , G2 Phase Cell Cycle Checkpoints/drug effects , NF-kappa B/drug effects , Ovarian Neoplasms/metabolism , TOR Serine-Threonine Kinases/drug effects , Animals , Cell Line, Tumor , Cell Survival , Female , Humans , In Vitro Techniques , Mice , Mice, Nude , NF-kappa B/metabolism , Neoplasm Transplantation , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/metabolism
3.
Biomed Res Int ; 2018: 3726091, 2018.
Article in English | MEDLINE | ID: mdl-29984231

ABSTRACT

Because NSCLC has poor overall prognosis and is frequently diagnosed at later stage, we aimed to seek novel diagnosis biomarkers or therapy target of the disease in this study. Fructose-1,6-bisphosphatase 1 (FBP1) is a rate-limiting enzyme in gluconeogenesis, which was usually lost in NSCLC due to abnormal methylation in promoter DNA sequence. The clinical data indicated that the methylation rate in FBP1 gene promoter was negatively related to the overall survival of the NSCLC patients. DNA methylation transferase inhibitor 5-aza treatment could significantly increase both expression levels of mRNA and protein in A549 cell line. On the other hand, silence of FBP1 in H460 cell line by using specific siRNA against FBP1 dramatically improved the cell proliferation and cell migration according to the date of FACS and transwell assays. All these findings implied the important roles of FBP1 expression in lung cancer development and progression and the potential use of the methylation status detected in FBP1 promoter region as a novel predictor for prognosis and therapeutic target for NSCLC patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , DNA Helicases/genetics , DNA Methylation , DNA-Binding Proteins/genetics , Lung Neoplasms/genetics , Adult , Aged , Cell Line, Tumor , Female , Fructose , Humans , Male , Middle Aged , Prognosis , Promoter Regions, Genetic , RNA-Binding Proteins
4.
Biomed Res Int ; 2018: 3972534, 2018.
Article in English | MEDLINE | ID: mdl-30046596

ABSTRACT

Ovarian cancer leads the worst prognosis among all types of gynecologic malignancies, and patients are often diagnosed at an advanced stage. Ovarian cancer also has a high rate of metastasis; however, the detailed mechanisms for ovarian cancer prone to metastasis remain unclear. In this study, we used continuous in vitro screening of the human ovarian cancer A2780 cell line to establish a cell line (A2780-M) which shows high invasiveness and motility. Compared to the parental cells, A2780-M cells express elevated protein levels of CD44, CD133, CD34, and ß-catenin. A2780-M cells are also more resistant to chemotherapeutic agents SN-38 and Docetaxel. Thus, the A2780-M cell line is a new ovarian metastatic cancer cell line that expresses tumor stem cell surface markers and adhesion-related membrane proteins and is with higher motility and invasiveness.


Subject(s)
Cell Line, Tumor , Neoplasm Proteins/metabolism , Ovarian Neoplasms/pathology , Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , Female , Humans , Neoplasm Metastasis , Neoplasms, Glandular and Epithelial , Ovarian Neoplasms/metabolism
5.
Biomed Res Int ; 2017: 9381513, 2017.
Article in English | MEDLINE | ID: mdl-29181409

ABSTRACT

BACKGROUND: Wogonin is a plant monoflavonoid and has been reported to induce apoptosis of cancer cells and show inhibitory effect on cancer cell growth. However, the detailed and underlying molecular mechanisms are not elucidated. In this study, we investigated the molecular and biological effects of wogonin in human ovarian A2780 cancer cells. MATERIALS AND METHODS: We determined the effects of wogonin on the changes of cell cycling and apoptotic responses of cells. Western blot analysis was used to measure the effects of wogonin on protein expressions. RESULTS: Our results showed that treatment with wogonin inhibited the cancer cell proliferation, decreased the percentage of G0/G1 subpopulation, and reduced invasiveness of A2780 cells. Exposure to wogonin also resulted in downregulated protein levels of estrogen receptor alpha (ER-α), VEGF, Bcl-2, and Akt and increased expressions of Bax and p53. In addition, exposure to wogonin increased caspase-3 cleavage and induced apoptosis in A2780 cells. Our study further showed that MPP, a specific ER-α inhibitor, significantly enhanced antitumor effects of wogonin in A2780 cells. CONCLUSION: Our results suggest a potential clinical impact of wogonin on management of ovarian cancer.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Flavanones/pharmacology , G1 Phase/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Neoplasm Proteins/biosynthesis , Ovarian Neoplasms/drug therapy , Resting Phase, Cell Cycle/drug effects , Cell Line, Tumor , Female , Humans , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology
6.
Oncotarget ; 8(28): 45577-45584, 2017 Jul 11.
Article in English | MEDLINE | ID: mdl-28715877

ABSTRACT

Transglutaminase 2 (TG2) plays important roles in cell survival and cancer progression. In this study, we examined TG2 expression in specimen of 194 patients diagnosed with non-small cell lung cancer (NSCLC), and found that the TG2 gene expression was significantly higher in lung cancer tissues as compared to paired incisal marginal tissues or normal tissues. Our data revealed that patients with lower level of TG2 expression detected in cancer tissues had longer disease free survival and overall survival as compared to the patients with higher TG2 expression. We also found that TG2 expression level correlated to NSCLC recurrence. These results suggest a potential prognosis impact of TG2 for NSCLC patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/mortality , GTP-Binding Proteins/genetics , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Transglutaminases/genetics , Adult , Aged , Biomarkers, Tumor , Carcinoma, Non-Small-Cell Lung/pathology , Female , GTP-Binding Proteins/metabolism , Gene Expression , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Prognosis , Proportional Hazards Models , Protein Glutamine gamma Glutamyltransferase 2 , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recurrence , Survival Analysis , Transglutaminases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...